Relay Therapeutics, Inc. (RLAY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$18.03+3.38%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RLAY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -38.9% |
| Our one-year growth estimate | diamond | 31.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 70.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
RLAY — earnings in line
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, the Company announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.2, of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subje…
Why it matters: Early results showed lesion shrinkage and symptom gains, but only 20 patients had response scans. More patient data can test whether the results hold.
Watch forNew ReInspire data show a volumetric response rate near or above 60%. Later scans confirm responses, with no treatment stops due to side effects.
Also watch forNew ReInspire data show a response rate below 60%, few confirmed responses, or treatment stops due to side effects.
Why it matters: The trial plans to test zovegalisib in younger children. A clear dose and continued enrollment would extend the study beyond adults and teens.
Watch forRelay reports that dose finding in children ages 6 to 11 is underway. It also shares a dose or enrollment update.
Also watch forRelay reports a pause, delay, or safety issue in pediatric dose finding.
Why it matters: Relay reported $642.1 million in cash at March 31 and said it had runway into 2029. More share sales or a lower cash balance could change that picture.
Worry ifThe Nov. 5 report shows cash below the March 31 level of $642.1 million and new ATM share sales.
Less concerning ifThe Nov. 5 report shows cash near or above $642.1 million, with no new ATM share sales reported.
Why it matters: The trial would test the zovegalisib, atirmociclib, and AI mix in frontline breast cancer. A delay or a changed plan would slow this program.
Watch forRelay starts the frontline Phase 3 trial in early 2027, after feedback from regulators. The trial uses the planned triplet and AI control design.
Also watch forRelay delays the trial beyond early 2027, changes the planned dose or design, or stops after talks with regulators.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$184 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $550 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,815 loss on $10,000 · 28.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.